Literature DB >> 23931490

Regression of choroidal neovascularization in response to systemic chemotherapy for cancer.

Annie W Hsu, Akrit Sodhi, Charles Eberhart, Silvia Montaner, Morton F Goldberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23931490      PMCID： PMC4005170          DOI： 10.1016/j.jcjo.2013.02.004

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN： 0008-4182            Impact factor:   1.882


× No keyword cloud information.
  10 in total

1.  Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials.

Authors:  Philip J Rosenfeld; Howard Shapiro; Lisa Tuomi; Mary Webster; Julee Elledge; Barbara Blodi
Journal:  Ophthalmology       Date:  2011-03       Impact factor: 12.079

Review 2.  Metronomic chemotherapy: new rationale for new directions.

Authors:  Eddy Pasquier; Maria Kavallaris; Nicolas André
Journal:  Nat Rev Clin Oncol       Date:  2010-06-08       Impact factor: 66.675

Review 3.  Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients.

Authors:  David M Brown; Carl D Regillo
Journal:  Am J Ophthalmol       Date:  2007-10       Impact factor: 5.258

4.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

5.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

Authors:  T Browder; C E Butterfield; B M Kräling; B Shi; B Marshall; M S O'Reilly; J Folkman
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

6.  Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.

Authors:  Karen Bjerg Pedersen; Anne Katrin Sjølie; Flemming Møller
Journal:  Acta Ophthalmol       Date:  2008-12-16       Impact factor: 3.761

Review 7.  Neovascular age-related macular degeneration: potential therapies.

Authors:  Aimee V Chappelow; Peter K Kaiser
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

Authors:  Jeffrey S Heier; David M Brown; Victor Chong; Jean-Francois Korobelnik; Peter K Kaiser; Quan Dong Nguyen; Bernd Kirchhof; Allen Ho; Yuichiro Ogura; George D Yancopoulos; Neil Stahl; Robert Vitti; Alyson J Berliner; Yuhwen Soo; Majid Anderesi; Georg Groetzbach; Bernd Sommerauer; Rupert Sandbrink; Christian Simader; Ursula Schmidt-Erfurth
Journal:  Ophthalmology       Date:  2012-10-17       Impact factor: 12.079

9.  Combination therapy for age-related macular degeneration.

Authors:  Samir Patel
Journal:  Retina       Date:  2009-06       Impact factor: 4.256

10.  Rationale for combination therapy in age-related macular degeneration.

Authors:  Richard F Spaide
Journal:  Retina       Date:  2009-06       Impact factor: 4.256
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.